 Connection
Grace Bosma to Humans
This is a "connection" page, showing publications Grace Bosma has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.050 |
|
|
|
-
Ambroggio L, Florin TA, Williamson K, Bosma G, Wagner BD, Yeomans L, Kim JH, Sucharew H, Macaluso M, Ruddy RM, Stringer KA, Shah SS. Urine Metabolites of Suspected Community-Acquired Pneumonia. J Infect Dis. 2025 Aug 14; 232(2):370-380.
Score: 0.006
-
Thibodeau P, Bosma GN, Hochheimer CJ, Syed A, Dieujuste N, Mann A, Fainstad T. The Moderating Effects of Moral Injury and Discrimination Trauma on Women Physician Trainees' Well-Being. J Gen Intern Med. 2025 Aug; 40(11):2679-2686.
Score: 0.006
-
Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr; 31(4):267.e1-267.e11.
Score: 0.006
-
Hlavin D, Bosma GN, Bolt MA, Sammel MD, Seyller N, Varty M. Evaluating the Accuracy of Off-Label Placement of Pulse Oximetry Sensors in Comparison to On-Label Placement in the Adult Cardiac Intensive Care Unit Patient Population. Dimens Crit Care Nurs. 2024 Jul-Aug 01; 43(4):176-183.
Score: 0.006
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
Score: 0.006
-
Fang J, Bosma G, Aisner D, McMahon C, Amaya M, Schwartz M, Kaiser J, Abbott D, Pan Z, Schowinsky J, Pang C, Gutman JA, Pollyea DA. White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia. Leuk Lymphoma. 2024 Jun; 65(6):800-807.
Score: 0.006
-
Perez de Acha O, Reiman L, Jayabalan DS, Walker ZJ, Bosma G, Keller AL, Parzych SE, Abbott D, Idler BM, Ribadeneyra D, Niesvizky R, Forsberg PA, Mark TM, Sherbenou DW. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Adv. 2023 11 14; 7(21):6430-6440.
Score: 0.005
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854.
Score: 0.005
-
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 10; 28(10):694.e1-694.e9.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|